ClinicalTrials.gg
RecruitingNCT07658534Updated Jun 22, 2026

A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection.

A Phase 2/3 interventional study of Ziresovir (AK0529) and Placebo in Respiratory Syncytial Virus Infections, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Recruiting at 9 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Respiratory Syncytial Virus Infections with a site in China — 8 open to participants now, 13 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · China.

Planned enrollment
11th of 25
290 · median 132
Started
2026
with 3 others
Phase 2/3
4 of 30
1 open now
Primary completion
2028-12
later than 12 of 12 live
Registered
28th of 30
by date
Lead sponsor
4 of 30
Shanghai Ark Biopharmaceutical Co., Ltd.

Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, this one is the 11th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2026, is one of 4 in phase 2/3, reaches primary completion later than 12 of the 12 other live ones, and was the 28th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

8 of the 30 studies in Respiratory Syncytial Virus Infections with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Respiratory Syncytial Virus Infections with a site in China, or all of them as a file.
02

Study summary

Respiratory syncytial virus (RSV) is recognized worldwide as a significant pathogen causing lower respiratory tract infection in infants, the elderly, and immunocompromised patients, which may cause bronchiolitis or pneumonia, and affect the cardiovascular system, central nervous system and the renal system, resulting in hospitalization and death risks in children and also high-risk adults, particularly the elderly. The purpose of this study is to evaluate the efficacy of Ziresovir (AK0529) compared to placebo with respect to the time to resolution of RSV lower respiratory tract disease (LRTD) symptoms.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Ziresovir
  • RSV
  • Chronic Respiratory Disease
  • Heart Disease
  • The Elderly
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-85 years (inclusive), regardless of gender.
  • Diagnosed with RSV infection by antigen or nucleic acid test within 36 hours before first dose.
  • Have at least one of the following high-risk conditions for RSV infection: Chronic respiratory disease; heart disease; status; other chronic disease; age ≥65 years.
  • Presence of at least one new LRTD symptom or worsening of a pre-existing LRTD symptom (specifically: cough, expectoration, wheezing, shortness of breath), with at least one individual symptom rated as moderate or severe (score 2 or 3 per RiiQ Symptom Scale).
  • Time from symptom onset (or worsening of pre-existing symptoms) to first dose ≤5 days. (Onset defined as time of first RSV-related symptom/sign confirmed by investigator; pre-existing symptoms are those due to underlying conditions)

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with influenza or COVID-19 infection within 7 days prior to providing .
  • Suspected bacterial co-infection.
  • Received any potentially anti-RSV agents (e.g., ribavirin, long-acting interferon) within 5 half-lives prior to the first study dose, or plans to use such agents during the study.
  • Received prohibited medications, or plans to use prohibited medications during the study.
  • Has a severe or unstable gastrointestinal, hepatic, renal, hematologic disorder, or .
  • Has a known allergy, , or intolerance to AK0529 or to any in the AK0529 or placebo formulation.
  • Female participants with a positive pregnancy test result, or who are breastfeeding.
  • Refusal to use effective during the trial period.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
290 participants (estimated)

Study arms

  • Experimental
    Active drug(200mg)

    The participants will receive 200 mg AK0529 twice daily for 5 days from D1 to D5.

    Drug: Ziresovir (AK0529)

  • Experimental
    Active drug(300mg)

    The participants will receive 300 mg AK0529 twice daily for 5 days from D1 to D5.

    Drug: Ziresovir (AK0529)

  • Placebo comparator
    Placebo

    The participants will receive placebo of 200 mg, or 300 mg twice daily for 5 days from D1 to D5.

    Drug: Placebo

Interventions

  • Active Substance: AK0529 Pharmaceutical Form: Enteric Capsules Route of Administration: Oral

  • DrugPlacebo

    Active Substance: Placebo Pharmaceutical Form: Enteric Capsules Route of Administration: Oral

06

What researchers measure

Primary outcomes

  1. Time from first dose to resolution of LRTD symptoms

    LRTD symptoms (cough, shortness of breath, wheezing, expectoration) are assessed by the RiiQ symptom scale, which includes 13 symptoms: 2 upper respiratory (stuffy nose, sore throat), 4 lower respiratory (cough, expectoration, wheezing, shortness of breath), and 7 systemic (feeling feverish, headache, body aches/pains, neck pain, trouble sleeping, tiredness, poor appetite). Each symptom is scored as None (0), Mild (1), Moderate (2), or Severe (3), with a total score range of 0-39.

    Time frame: Up to Day 27

Secondary outcomes

  1. Resolution rates of LRTD symptoms after treatment

    LRTD symptoms (cough, shortness of breath, wheezing, expectoration) are assessed by the RiiQ symptom scale, which includes 13 symptoms: 2 upper respiratory (stuffy nose, sore throat), 4 lower respiratory (cough, expectoration, wheezing, shortness of breath), and 7 systemic (feeling feverish, headache, body aches/pains, neck pain, trouble sleeping, tiredness, poor appetite). Each symptom is scored as None (0), Mild (1), Moderate (2), or Severe (3), with a total score range of 0-39.

    Time frame: Day 3, Day 6, Day 13, Day 27

  2. Time from first dose to resolution of upper respiratory, systemic, and total symptoms

    Upper respiratory, systemic, and total symptoms are assessed by the RiiQ symptom scale, which includes 13 symptoms: 2 upper respiratory (stuffy nose, sore throat), 4 lower respiratory (cough, expectoration, wheezing, shortness of breath), and 7 systemic (feeling feverish, headache, body aches/pains, neck pain, trouble sleeping, tiredness, poor appetite). Each symptom is scored as None (0), Mild (1), Moderate (2), or Severe (3), with a total score range of 0-39.

    Time frame: Up to Day 27

  3. Resolution rate of upper respiratory, systemic, and total symptoms

    Upper respiratory, systemic, and total symptoms are assessed by the RiiQ symptom scale, which includes 13 symptoms: 2 upper respiratory (stuffy nose, sore throat), 4 lower respiratory (cough, expectoration, wheezing, shortness of breath), and 7 systemic (feeling feverish, headache, body aches/pains, neck pain, trouble sleeping, tiredness, poor appetite). Each symptom is scored as None (0), Mild (1), Moderate (2), or Severe (3), with a total score range of 0-39.

    Time frame: Day 3, Day 6, Day 13, Day 27

  4. Change from baseline in RSV viral load (VL)

    RSV VL in nasopharyngeal samples from participants will be measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR)

    Time frame: Day 2 to Day6, Day 13, Day 27

  5. Change from baseline in RiiQ total score and domain scores

    RSV symptoms are assessed by the RiiQ symptom scale, which includes 13 symptoms: 2 upper respiratory (stuffy nose, sore throat), 4 lower respiratory (cough, expectoration, wheezing, shortness of breath), and 7 systemic (feeling feverish, headache, body aches/pains, neck pain, trouble sleeping, tiredness, poor appetite). Each symptom is scored as None (0), Mild (1), Moderate (2), or Severe (3), with a total score range of 0-39.

    Time frame: Day 3, Day 6, Day 13, Day 27

  6. Trough plasma concentration of AK0529

    Plasma concentration of AK0529 is reported. This outcome measure is planned to be analyzed for specified arm only. In this outcome measure, only those time points for which individual participants had data are reported.

    Time frame: Day 5

  7. Incidence and severity of treatment-emergent AEs (TEAEs), SAEs, and other AEs

    An adverse events (AEs) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Any clinically significant physical examinations, vital signs, clinical laboratory tests (including biochemistry, hematology, cardiac enzymes and urine analysis), 12-lead electrocardiograms (ECGs) and spirometry results were recorded as adverse events. Any AE which occurred at or after the initial administration of study intervention through the end of the study (that is, Day 27) was considered treatment-emergent. A Serious Adverse Events (SAEs) is any adverse event that results in death, is life-threatening, requires hospitalization, causes persistent disability, or results in a congenital anomaly. The severity of AEs/ SAEs is categorized by CTCAE6.0.

    Time frame: Up to Day 27

Other outcomes

  1. Proportion of participants hospitalized

    Proportion of outpatient participants who experienced at least one hospitalization during the study period.

    Time frame: Up to Day 27

  2. Hospitalization duration

    Duration of hospitalization among participants who were hospitalized during the study period.

    Time frame: Up to Day 27

  3. Supplemental oxygen use

    The proportion of participants who received supplemental oxygen at any point during the study, as well as the duration of use.

    Time frame: Up to Day 27

  4. ICU admission rate

    The proportion of participants with at least one ICU admission during the study.

    Time frame: Up to Day 27

07

Study locations

6 of 9 sites recruiting
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality, China
    Recruiting
  • Guangzhou Medical University Panyu Central Hospital
    Guangzhou, Guangdong, China
    Not yet recruiting
  • Cangzhou Hospital of Integrated TCM-WM
    Cangzhou, Hebei, China
    Recruiting
  • The First Affiliated Hospital of Nanyang Medical College
    Nanyang, Henan, China
    Recruiting
  • Henan Infectious Disease Hospital (The Sixth People's Hospital of Zhengzhou)
    Zhengzhou, Henan, China
    Not yet recruiting
  • Wuhan Sixth Hospital
    Wuhan, Hubei, China
    Recruiting
  • Zhejiang Hospital
    Hangzhou, Zhejiang, China
    Not yet recruiting
  • People's Hospital of Rui'an City
    Rui’an, Zhejiang, China
    Recruiting
  • Taizhou Hospital of Zhejiang Province
    Taizhou, Zhejiang, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
Jun 22, 2026
StartActual
Mar 3, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Jan 2029
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07658534
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Mar 3, 2026
Primary completion
Dec 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Jun 22, 2026

Study contacts

Chao Yu, Mater
Contact
chao.yu@arkbiosciences.com
+86 021-50681677

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziresovir

Start the discussion